Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Dynastat
Parecoxib is a prodrug of valdecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, belonging to the class of nonsteroidal anti-inflammatory drugs (NSAIDs). It is administered intravenously or intramuscularly for the short-term management of moderate to severe acute pain, including postoperative pain, and is converted to its active form, valdecoxib, in the body. By selectively inhibiting COX-2, parecoxib reduces the production of prostaglandins, key mediators of pain and inflammation, while minimizing the effects on COX-1, which is involved in protecting the stomach lining and promoting platelet function. This selectivity aims to reduce gastrointestinal side effects associated with traditional NSAIDs.
For short-term management of moderate to severe acute pain, including postoperative pain.
Increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. Increased risk of serious gastrointestinal adverse events, including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal.
Outcome:
Increased risk of bleeding
Mechanism:
Parecoxib can displace warfarin from protein binding sites and inhibit platelet function.
Outcome:
Increased methotrexate toxicity
Mechanism:
Reduced renal clearance of methotrexate.
Outcome:
May slightly decrease parecoxib absorption
Mechanism:
Altered gastric pH.
Most likely new formulation: extended-release parecoxib for chronic pain management (Year: 2026, 30% confidence)
Based on current usage trends and safety profile, there is a low probability (<5%) of regulatory changes impacting parecoxib's availability in the next 5 years.
Nonsteroidal anti-inflammatory drug (NSAID), COX-2 inhibitor
Coxib